Beijing Science Sun Pharmaceutical Co Ltd Net Asset Quality Index
Beijing Science Sun Pharmaceutical Co Ltd net asset quality index. Beijing Science Sun Pharmaceutical Co Ltd (300485) has a Net Asset Quality Index of 96.1% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥3.36 Billion minus total liabilities of CN¥131.13 Million yields net assets of CN¥3.23 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See net assets of Beijing Science Sun Pharmaceutical Co Lt for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Beijing Science Sun Pharmaceutical Co Ltd (2011–2025)
Net asset quality index of Beijing Science Sun Pharmaceutical Co Ltd from 2011 to 2025. This chart shows how Beijing Science Sun Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 15 annual periods from 2011 to 2025. As of June 2026, the index stands at 96.1%, representing net assets of CN¥3.23 Billion against total assets of CN¥3.36 Billion CNY. Check 300485 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Beijing Science Sun Pharmaceutical Co Ltd Net Asset Quality Index by Year (2011–2025)
Beijing Science Sun Pharmaceutical Co Ltd net asset quality index by year from 2011 to 2025. The table below presents the year-by-year Net Asset Quality Index for Beijing Science Sun Pharmaceutical Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market value of Beijing Science Sun Pharmaceutical Co Lt.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 95.1% | CN¥3.39 Billion | CN¥3.57 Billion | CN¥175.95 Million | ▼ -0.2 pp |
| 2024 | 95.3% | CN¥3.39 Billion | CN¥3.55 Billion | CN¥166.48 Million | ▼ -0.4 pp |
| 2023 | 95.7% | CN¥3.47 Billion | CN¥3.62 Billion | CN¥154.61 Million | ▲ +0.1 pp |
| 2022 | 95.6% | CN¥3.41 Billion | CN¥3.57 Billion | CN¥157.10 Million | ▼ -0.9 pp |
| 2021 | 96.5% | CN¥3.28 Billion | CN¥3.40 Billion | CN¥118.54 Million | ▲ +1.2 pp |
| 2020 | 95.3% | CN¥2.85 Billion | CN¥2.99 Billion | CN¥141.13 Million | ▼ -1.4 pp |
| 2019 | 96.6% | CN¥2.71 Billion | CN¥2.81 Billion | CN¥94.26 Million | ▲ +4.1 pp |
| 2018 | 92.6% | CN¥2.56 Billion | CN¥2.76 Billion | CN¥205.07 Million | ▼ -2.0 pp |
| 2017 | 94.5% | CN¥2.32 Billion | CN¥2.45 Billion | CN¥133.91 Million | ▼ -0.1 pp |
| 2016 | 94.6% | CN¥2.10 Billion | CN¥2.22 Billion | CN¥118.63 Million | ▼ -2.2 pp |
| 2015 | 96.8% | CN¥1.88 Billion | CN¥1.94 Billion | CN¥62.00 Million | ▲ +6.8 pp |
| 2014 | 90.0% | CN¥646.64 Million | CN¥718.35 Million | CN¥71.71 Million | ▼ -1.2 pp |
| 2013 | 91.3% | CN¥493.71 Million | CN¥541.04 Million | CN¥47.33 Million | ▲ +0.2 pp |
| 2012 | 91.1% | CN¥359.96 Million | CN¥395.13 Million | CN¥35.18 Million | ▲ +2.7 pp |
| 2011 | 88.4% | CN¥247.37 Million | CN¥279.77 Million | CN¥32.39 Million | — |